AstraZeneca PLC (AZN)vsLENSAR Inc (LNSR)
AZN
AstraZeneca PLC
$160.17
+2.23%
HEALTHCARE · Cap: $252.33B
LNSR
LENSAR Inc
$7.60
-5.59%
HEALTHCARE · Cap: $101.36M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 101729% more annual revenue ($61.37B vs $60.26M). LNSR leads profitability with a 57.6% profit margin vs 17.0%. AZN trades at a lower P/E of 24.3x. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
LNSR
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
-84.5%
Fair Value
$6.73
Current Price
$7.60
$0.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Every $100 of equity generates 36 in profit
Keeps 58 of every $100 in revenue as profit
Conservative balance sheet, low leverage
18.4% revenue growth
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : LNSR
The strongest argument for LNSR centers on Return on Equity, Profit Margin, Debt/Equity. Profitability is solid with margins at 57.6% and operating margin at 12.9%. Revenue growth of 18.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : LNSR
The primary concerns for LNSR are EPS Growth, Market Cap, Piotroski F-Score. A P/E of 43.4x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a mature stock while LNSR is a growth play — different risk/reward profiles.
LNSR carries more volatility with a beta of 0.88 — expect wider price swings.
LNSR is growing revenue faster at 18.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 51/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
LENSAR Inc
HEALTHCARE · MEDICAL DEVICES · USA
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?